Showing results (41-50 of 208) with videos related to
Sort By:
Pageof 21
Molecular Cancer Therapeutics|January 26, 2017
Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid MalignanciesMonish R Makena, Balakrishna Koneru, Thinh H Nguyen, et al.Medical Science Educator|August 30, 2021
Performing Under Pressure: Varsity Athletes Excel in Medical SchoolLindsay C Strowd, Hong Gao, Mary Claire O'Brien, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastomaHua Fang, Theresa M Harned, Ondrej Kalous, et al.Drug and Alcohol Dependence|December 17, 2009
Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology ProgramRobert A Schnoll, Elisa Martinez, Kristina L Tatum, et al.Journal of the National Cancer Institute|July 12, 2007
Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptideNino Keshelava, Elai Davicioni, Zesheng Wan, et al.Addictive Behaviors|October 7, 2009
Correlates of smoking cessation self-efficacy in a community sample of smokersElisa Martinez, Kristina L Tatum, Marcella Glass, et al.Blood|May 16, 2002
Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and azurophil granule exocytosisLeonid S Metelitsa, Stephen D Gillies, Michael Super, et al.Addictive Behaviors|September 28, 2010
Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatmentRobert A Schnoll, Elisa Martinez, Kristina L Tatum, et al.Pediatric Blood & Cancer|October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing programRaushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.Cancer Immunology, Immunotherapy : CII|February 26, 2015
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastomaDiana Seidel, Anastasia Shibina, Nikolai Siebert, et al.Pageof 21